<DOC>
	<DOC>NCT00211523</DOC>
	<brief_summary>This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.</brief_summary>
	<brief_title>Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Antimicrobial Cationic Peptides</mesh_term>
	<criteria>Males and females, ages 13 and up, exhibiting high levels of facial P. acnes Presence of inflammatory and noninflammatory lesions Acne conglobata, acne fulminans, or secondary acne (chlorine, druginduced acne, etc.) Active facial cysts</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>acne</keyword>
	<keyword>acne vulgaris</keyword>
	<keyword>MBI 226</keyword>
	<keyword>Propionibacterium acnes</keyword>
	<keyword>lesion counts</keyword>
	<keyword>lesions</keyword>
	<keyword>inflammatory</keyword>
	<keyword>non-inflammatory</keyword>
	<keyword>topical</keyword>
</DOC>